• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

FIGO 2018 分期 IIICp 期宫颈癌患者转移淋巴结数量和淋巴结比值对预后的预测价值:一项多中心回顾性研究。

Predictive value of number of metastatic lymph nodes and lymph node ratio for prognosis of patients with FIGO 2018 stage IIICp cervical cancer: a multi-center retrospective study.

机构信息

Department of Midwifery, School of Health, Dongguan Polytechnic, Dongguan, 523808, China.

Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.

出版信息

BMC Cancer. 2024 Aug 13;24(1):1005. doi: 10.1186/s12885-024-12784-8.

DOI:10.1186/s12885-024-12784-8
PMID:39138415
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11320992/
Abstract

BACKGROUND

To identify the cut-off values for the number of metastatic lymph nodes (nMLN) and lymph node ratio (LNR) that can predict outcomes in patients with FIGO 2018 IIICp cervical cancer (CC).

METHODS

Patients with CC who underwent radical hysterectomy with pelvic lymphadenectomy were identified for a propensity score-matched (PSM) cohort study. A receiver operating characteristic (ROC) curve analysis was performed to determine the critical nMLN and LNR values. Five-year overall survival (OS) and disease-free survival (DFS) rates were compared using Kaplan-Meier and Cox proportional hazard regression analyses.

RESULTS

This study included 3,135 CC patients with stage FIGO 2018 IIICp from 47 Chinese hospitals between 2004 and 2018. Based on ROC curve analysis, the cut-off values for nMLN and LNR were 3.5 and 0.11, respectively. The final cohort consisted of nMLN ≤ 3 (n = 2,378) and nMLN > 3 (n = 757) groups and LNR ≤ 0.11 (n = 1,748) and LNR > 0.11 (n = 1,387) groups. Significant differences were found in survival between the nMLN ≤ 3 vs the nMLN > 3 (post-PSM, OS: 76.8% vs 67.9%, P = 0.003; hazard ratio [HR]: 1.411, 95% confidence interval [CI]: 1.108-1.798, P = 0.005; DFS: 65.5% vs 55.3%, P < 0.001; HR: 1.428, 95% CI: 1.175-1.735, P < 0.001), and the LNR ≤ 0.11 and LNR > 0.11 (post-PSM, OS: 82.5% vs 76.9%, P = 0.010; HR: 1.407, 95% CI: 1.103-1.794, P = 0.006; DFS: 72.8% vs 65.1%, P = 0.002; HR: 1.347, 95% CI: 1.110-1.633, P = 0.002) groups.

CONCLUSIONS

This study found that nMLN > 3 and LNR > 0.11 were associated with poor prognosis in CC patients.

摘要

背景

确定转移性淋巴结数量(nMLN)和淋巴结比率(LNR)的截断值,以预测 FIGO 2018 期 IIICp 宫颈癌(CC)患者的结局。

方法

本研究通过倾向性评分匹配(PSM)队列研究,纳入了 2004 年至 2018 年期间 47 家中国医院接受根治性子宫切除术和盆腔淋巴结清扫术的 CC 患者。采用受试者工作特征(ROC)曲线分析确定临界 nMLN 和 LNR 值。采用 Kaplan-Meier 和 Cox 比例风险回归分析比较 5 年总生存率(OS)和无病生存率(DFS)。

结果

本研究共纳入了来自 47 家中国医院的 3135 例 FIGO 2018 期 IIICp CC 患者。基于 ROC 曲线分析,nMLN 和 LNR 的截断值分别为 3.5 和 0.11。最终队列分为 nMLN≤3(n=2378)和 nMLN>3(n=757)组以及 LNR≤0.11(n=1748)和 LNR>0.11(n=1387)组。在生存方面,nMLN≤3 与 nMLN>3(PSM 后,OS:76.8% vs 67.9%,P=0.003;风险比 [HR]:1.411,95%置信区间 [CI]:1.108-1.798,P=0.005;DFS:65.5% vs 55.3%,P<0.001;HR:1.428,95% CI:1.175-1.735,P<0.001)以及 LNR≤0.11 和 LNR>0.11(PSM 后,OS:82.5% vs 76.9%,P=0.010;HR:1.407,95% CI:1.103-1.794,P=0.006;DFS:72.8% vs 65.1%,P=0.002;HR:1.347,95% CI:1.110-1.633,P=0.002)两组之间存在显著差异。

结论

本研究发现 nMLN>3 和 LNR>0.11 与 CC 患者的预后不良相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/753b/11320992/9cfbf61aa31a/12885_2024_12784_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/753b/11320992/055252ede4a6/12885_2024_12784_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/753b/11320992/96fa3a6a7284/12885_2024_12784_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/753b/11320992/9cfbf61aa31a/12885_2024_12784_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/753b/11320992/055252ede4a6/12885_2024_12784_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/753b/11320992/96fa3a6a7284/12885_2024_12784_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/753b/11320992/9cfbf61aa31a/12885_2024_12784_Fig3_HTML.jpg

相似文献

1
Predictive value of number of metastatic lymph nodes and lymph node ratio for prognosis of patients with FIGO 2018 stage IIICp cervical cancer: a multi-center retrospective study.FIGO 2018 分期 IIICp 期宫颈癌患者转移淋巴结数量和淋巴结比值对预后的预测价值:一项多中心回顾性研究。
BMC Cancer. 2024 Aug 13;24(1):1005. doi: 10.1186/s12885-024-12784-8.
2
Lymph node ratio as an indicator of nodal status in the assessment of survival and recurrence in vulvar cancer: A cohort study.淋巴结比率作为评估外阴癌生存和复发的淋巴结状态指标:一项队列研究。
Womens Health (Lond). 2024 Jan-Dec;20:17455057241285396. doi: 10.1177/17455057241285396.
3
The prognostic value of lymph node ratio in stage IIIC cervical cancer patients triaged to primary treatment by radical hysterectomy with systematic pelvic and para-aortic lymphadenectomy.淋巴结比值在经广泛子宫切除术和系统盆腔及主动脉旁淋巴结切除术行初始治疗的 IIIC 期宫颈癌患者中的预后价值。
J Gynecol Oncol. 2020 Jan;31(1):e1. doi: 10.3802/jgo.2020.31.e1. Epub 2019 Jun 24.
4
Lymph Node Ratio Is a Strong Prognostic Factor in Patients with Early-Stage Cervical Cancer Undergoing Minimally Invasive Radical Hysterectomy.淋巴结比率是行微创根治性子宫切除术的早期宫颈癌患者的一个强有力的预后因素。
Yonsei Med J. 2021 Mar;62(3):231-239. doi: 10.3349/ymj.2021.62.3.231.
5
Predictive Value of the Number of Harvested Lymph Nodes and Cut-Off for Lymph Node Ratio in the Prognosis of Stage II and III Colorectal Cancer Patients.II期和III期结直肠癌患者预后中淋巴结收获数量及淋巴结比率临界值的预测价值
J Invest Surg. 2019 Jan;32(1):1-7. doi: 10.1080/08941939.2017.1369605. Epub 2017 Oct 3.
6
Nodal status, number of lymph nodes examined, and lymph node ratio: what defines prognosis after resection of colon adenocarcinoma?淋巴结状态、检查的淋巴结数量和淋巴结比率:切除结肠癌后,哪些因素决定预后?
J Am Coll Surg. 2013 Dec;217(6):1090-100. doi: 10.1016/j.jamcollsurg.2013.07.404. Epub 2013 Sep 14.
7
Lymph Node Ratio Can Better Predict Prognosis than Absolute Number of Positive Lymph Nodes in Operable Cervical Carcinoma.在可手术宫颈癌中,淋巴结比值比阳性淋巴结绝对数能更好地预测预后。
Oncol Res Treat. 2020;43(3):87-95. doi: 10.1159/000505032. Epub 2020 Jan 14.
8
The effect of lymph node ratio on the surgical outcomes in patients with colorectal cancer.淋巴结比率对结直肠癌患者手术结局的影响。
Sci Rep. 2024 Jul 31;14(1):17689. doi: 10.1038/s41598-024-68576-4.
9
[Long-term oncological outcomes after laparoscopic versus abdominal radical hysterectomy in stage I a2- II a2 cervical cancer: a matched cohort study].[I a2-II a2期宫颈癌腹腔镜与开腹根治性子宫切除术后的长期肿瘤学结局:一项配对队列研究]
Zhonghua Fu Chan Ke Za Zhi. 2015 Dec;50(12):894-901.
10
The prognostic value of the number of positive lymph nodes and the lymph node ratio in early-stage cervical cancer.早期宫颈癌中阳性淋巴结数量和淋巴结比率的预后价值。
Acta Obstet Gynecol Scand. 2022 May;101(5):550-557. doi: 10.1111/aogs.14316. Epub 2022 Feb 26.

引用本文的文献

1
Risk stratification of node-positive early-stage cervical cancer treated with radical hysterectomy followed by chemoradiotherapy: a retrospective single-center study.根治性子宫切除术后同步放化疗治疗的淋巴结阳性早期宫颈癌的风险分层:一项回顾性单中心研究
Radiat Oncol. 2025 May 13;20(1):73. doi: 10.1186/s13014-025-02655-2.

本文引用的文献

1
Initial treatment for FIGO 2018 stage IIIC cervical cancer based on histological type: A 14-year multicenter study.基于组织学类型的 2018 年 FIGO 分期 IIIC 期宫颈癌的初始治疗:一项 14 年多中心研究。
Cancer Med. 2023 Oct;12(19):19617-19632. doi: 10.1002/cam4.6586. Epub 2023 Sep 28.
2
Treatment of FIGO 2018 stage IIIC cervical cancer with different local tumor factors.FIGO 2018 期 IIIC 宫颈癌不同局部肿瘤因素的治疗。
BMC Cancer. 2023 May 9;23(1):421. doi: 10.1186/s12885-023-10801-w.
3
Impact of different postoperative adjuvant therapies on the survival of early-stage cervical cancer patients with one intermediate-risk factor: A multicenter study of 14 years.
不同术后辅助治疗对伴有 1 个中危因素的早期宫颈癌患者生存的影响:14 年多中心研究。
J Obstet Gynaecol Res. 2023 Jun;49(6):1579-1591. doi: 10.1111/jog.15632. Epub 2023 Mar 14.
4
Treatment Strategies and Prognostic Factors of 2018 FIGO Stage IIIC Cervical Cancer: A Review.2018FIGO 期 IIIC 宫颈癌的治疗策略和预后因素:综述。
Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221086403. doi: 10.1177/15330338221086403.
5
Discussion on the rationality of FIGO 2018 stage IIIC for cervical cancer with oncological outcomes: a cohort study.基于肿瘤学结局探讨2018年国际妇产科联盟(FIGO)宫颈癌IIIC期分期的合理性:一项队列研究
Ann Transl Med. 2022 Jan;10(2):122. doi: 10.21037/atm-21-6374.
6
The prognostic value of the number of positive lymph nodes and the lymph node ratio in early-stage cervical cancer.早期宫颈癌中阳性淋巴结数量和淋巴结比率的预后价值。
Acta Obstet Gynecol Scand. 2022 May;101(5):550-557. doi: 10.1111/aogs.14316. Epub 2022 Feb 26.
7
Prognostic value of tumor measurement parameters and SCC-Ag changes in patients with locally-advanced cervical cancer.局部晚期宫颈癌患者肿瘤测量参数和 SCC-Ag 变化的预后价值。
Radiat Oncol. 2022 Jan 10;17(1):6. doi: 10.1186/s13014-021-01978-0.
8
The Impact of Histological Subtype on Survival Outcome of Patients with Stage IIB-IVA Cervical Cancer Who Received Definitive Radiotherapy.组织学分型对接受根治性放疗的 IIB-IVA 期宫颈癌患者生存结局的影响。
Tohoku J Exp Med. 2021 Dec;255(4):303-313. doi: 10.1620/tjem.255.303.
9
Cancer of the cervix uteri: 2021 update.子宫颈癌:2021 年更新。
Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1(Suppl 1):28-44. doi: 10.1002/ijgo.13865.
10
What is the impact of corpus uterine invasion on oncologic outcomes in surgically treated cervical cancer?子宫体侵犯对手术治疗宫颈癌的肿瘤学结局有何影响?
J Obstet Gynaecol Res. 2021 Oct;47(10):3634-3643. doi: 10.1111/jog.14953. Epub 2021 Aug 1.